1st June 2021
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, post-fund raising, it has started the planned studies on its pipeline assets NXP002 (new form of tranilast) and NXP004 (undisclosed oncology drug). Download News